These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 9797014)
1. Intratumoral aromatase model: the effects of letrozole (CGS 20267). Brodie A; Lu Q; Yue W; Wang J; Liu Y Breast Cancer Res Treat; 1998; 49 Suppl 1():S23-6; discussion S33-7. PubMed ID: 9797014 [TBL] [Abstract][Full Text] [Related]
2. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790 [TBL] [Abstract][Full Text] [Related]
3. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045 [TBL] [Abstract][Full Text] [Related]
4. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. Brodie AH; Jelovac D; Long B J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522 [TBL] [Abstract][Full Text] [Related]
5. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621 [TBL] [Abstract][Full Text] [Related]
6. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Long BJ; Jelovac D; Thiantanawat A; Brodie AM Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443 [TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors and their antitumor effects in model systems. Brodie A; Lu Q; Liu Y; Long B Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110 [TBL] [Abstract][Full Text] [Related]
8. Aromatase and breast cancer. Brodie A; Sabnis G; Jelovac D J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978 [TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. Kijima I; Itoh T; Chen S J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272 [TBL] [Abstract][Full Text] [Related]
10. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. Long BJ; Jelovac D; Handratta V; Thiantanawat A; MacPherson N; Ragaz J; Goloubeva OG; Brodie AM J Natl Cancer Inst; 2004 Mar; 96(6):456-65. PubMed ID: 15026471 [TBL] [Abstract][Full Text] [Related]
12. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754 [TBL] [Abstract][Full Text] [Related]
13. Aromatase and its inhibitors. Brodie A; Lu Q; Long B J Steroid Biochem Mol Biol; 1999; 69(1-6):205-10. PubMed ID: 10418994 [TBL] [Abstract][Full Text] [Related]
14. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Brodie A; Jelovac D; Long BJ Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500 [TBL] [Abstract][Full Text] [Related]
15. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674 [TBL] [Abstract][Full Text] [Related]
16. Model systems: mechanisms involved in the loss of sensitivity to letrozole. Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659 [TBL] [Abstract][Full Text] [Related]
17. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602 [TBL] [Abstract][Full Text] [Related]
18. Drug and hormone interactions of aromatase inhibitors. Dowsett M Endocr Relat Cancer; 1999 Jun; 6(2):181-5. PubMed ID: 10731107 [TBL] [Abstract][Full Text] [Related]
19. Aromatase and COX-2 expression in human breast cancers. Brodie AM; Lu Q; Long BJ; Fulton A; Chen T; Macpherson N; DeJong PC; Blankenstein MA; Nortier JW; Slee PH; van de Ven J; van Gorp JM; Elbers JR; Schipper ME; Blijham GH; Thijssen JH J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):41-7. PubMed ID: 11850206 [TBL] [Abstract][Full Text] [Related]
20. New approaches to the understanding of tamoxifen action and resistance. Berstein LM; Zheng H; Yue W; Wang JP; Lykkesfeldt AE; Naftolin F; Harada H; Shanabrough M; Santen RJ Endocr Relat Cancer; 2003 Jun; 10(2):267-77. PubMed ID: 12790788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]